BACKGROUND
Ivacaftor is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. We assessed its use in children aged 12 to <24 months.
METHODS
The ARRIVAL study is a phase 3, single-arm, two-part, multicentre study. Eligible children were